Abstract
Inhibition of genes is a powerful approach to study their function. While RNA interference is a widely used method to achieve this goal, mounting evidence indicates that such an approach is prone to off-target effects. An alternative approach to gene function inhibition is genetic mutation, such as the CRISPR/cas9 method. A recent report, however, demonstrated that genetic mutation and inhibition of gene expression do not always give corresponding results. This can be explained by off-target effects, but it was recently shown, at least in one case, that these differences are the result of a compensatory mechanism induced only by genetic mutation. We present here a combination of RNA inhibition and CRISPR/cas9 methods to identify possible off targets as well as potential compensatory effects. This approach is demonstrated by testing a possible role for Sema4B in glioma biology, in which our results implicate Sema4B as having a critical function. In stark contrast, by using shRNA over CRISPR/cas9 combined methodology, we clearly demonstrate that the Sema4B targeted shRNA effects on cell proliferation is the result of off-target effects. Nevertheless, it also revealed that certain splice variants of Sema4B are important for the ab...Continue Reading
References
Jan 15, 1997·The Journal of Clinical Investigation·L De FranceschiG Berton
Aug 11, 2005·Nucleic Acids Research·Xiaoyu LinYu Shen
Sep 2, 2006·Nucleic Acids Research·Angus T De SouzaRoger G Ulrich
Feb 8, 2007·Proceedings of the National Academy of Sciences of the United States of America·Richard HarrisonDaniela Delneri
Jun 15, 2007·Trends in Genetics : TIG·Ben-Yang Liao, Jianzhi Zhang
Jun 23, 2007·Briefings in Functional Genomics & Proteomics·Ivana BarbaricT Neil Dear
Jul 6, 2007·Cancer Biology & Therapy·Bedri KarakasBen Ho Park
Sep 22, 2009·FEBS Letters·Rachel YoungJean-Luc Vilotte
Jan 1, 2010·Nature Reviews. Drug Discovery·Aimee L Jackson, Peter S Linsley
Apr 9, 2010·Brain : a Journal of Neurology·Sascha SeidelTill Acker
Aug 26, 2010·Science Signaling·Albrecht MoritzMichael J Comb
Jul 14, 2011·PloS One·Daniel R CaffreyJason D Hughes
Jan 11, 2012·Human Gene Therapy·Zhongping YuanZhiwei Wu
Aug 22, 2012·Experimental Cell Research·Liuqi YangXiujie Wang
Jan 30, 2014·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Hong JianJie Zhang
Mar 4, 2014·Nature Biotechnology·Jeffry D Sander, J Keith Joung
Aug 7, 2014·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Hong JianShun Lu
Dec 24, 2014·Developmental Cell·Fatma O KokNathan D Lawson
Mar 10, 2015·Cellular Signalling·Hong JianShun Lu
Jun 10, 2015·Oncotarget·Chunyan LiXuemei Lu
Jul 15, 2015·Nature·Andrea RossiDidier Y R Stainier
Oct 16, 2015·ENeuro·Liat Ben-GigiOded Behar
Nov 18, 2015·Molecular Therapy. Nucleic Acids·Xiao-Hui ZhangShi-Hua Yang
Apr 26, 2016·Nature Biotechnology·Bastiaan EversRene Bernards
May 10, 2016·Nature Biotechnology·David W MorgensMichael C Bassik
Jul 14, 2017·PLoS Genetics·Mohamed A El-Brolosy, Didier Y R Stainier
Citations
Jan 22, 2020·Epigenomics·Lingfang FengJianlin Lou
Mar 11, 2020·PloS One·Morgane CanonnePatricia Renard
Sep 11, 2019·Current Protocols in Molecular Biology·Christopher J GiulianoJason M Sheltzer
Feb 24, 2019·Journal of Cell Science·Natania Casden, Oded Behar
Aug 5, 2019·Cellular and Molecular Life Sciences : CMLS·Blanca Martínez-ArribasDolores González-Pacanowska
Oct 20, 2020·Adipocyte·Markus MandlWerner Zwerschke
Jun 24, 2020·Cancer Research·Yibin XuNouri Neamati
Oct 30, 2020·Cancers·Euna JeongSukjoon Yoon
May 21, 2021·Briefings in Bioinformatics·Thomas GaudeletJake P Taylor-King
Jul 3, 2021·Cancers·Laura V BownesElizabeth A Beierle
Jul 17, 2021·PloS One·James KenneyC Michael DiPersio
Sep 23, 2021·Oncogenesis·Yaoxin GaoWenzheng Jiang
Nov 17, 2019·EBioMedicine·Wenyu WangJing Tang